Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503273 | 0.91 | CYP1A2 (0.42) | CYP1A2RAB9ASIRT2SIRT1PDE2A | |
| SCHEMBL6496733 | 0.90 | ALOX5AP (0.47) | RAB9AALOX5APSMN1; SMN2 | |
| SCHEMBL6493004 | 0.88 | PDE2A (0.47) | CYP1A2RAB9ASIRT2SIRT1ALOX5AP | |
| SCHEMBL6488571 | 0.87 | PDE2A (0.36) | PDE2A | |
| SCHEMBL6491050 | 0.84 | LMNA (0.38) | CYP1A2RAB9APDE2ALMNASMN1; SMN2 | |
| SCHEMBL6489265 | 0.84 | TARBP2 (0.42) | LMNASMN1; SMN2 | |
| SCHEMBL6488966 | 0.83 | RXRA (0.41) | RAB9AALOX5APSMN1; SMN2 | |
| SCHEMBL6489130 | 0.83 | MAPT (0.40) | RAB9ASIRT2SIRT1LMNASMN1; SMN2 | |
| SCHEMBL6301641 | 0.83 | PDE2A (0.51) | CYP1A2RAB9ASIRT2SIRT1PDE2A | |
| SCHEMBL6490645 | 0.83 | PTGDR (0.44) | CYP1A2RAB9AALOX5APLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | CYP1A2 247/4885RAB9A 2599/4885SIRT2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.